CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Short Interest Update

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) was the recipient of a large increase in short interest in the month of July. As of July 31st, there was short interest totalling 5,100 shares, an increase of 34.2% from the July 15th total of 3,800 shares. Based on an average daily volume of 12,400 shares, the short-interest ratio is presently 0.4 days. Approximately 0.1% of the shares of the company are sold short.

Wall Street Analyst Weigh In

CLGN has been the topic of a number of recent research reports. EF Hutton Acquisition Co. I upgraded shares of CollPlant Biotechnologies to a “strong-buy” rating in a research note on Monday, August 5th. HC Wainwright restated a “buy” rating and issued a $11.00 price target on shares of CollPlant Biotechnologies in a research report on Thursday, May 30th.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Pinnacle Associates Ltd. increased its position in CollPlant Biotechnologies by 6.4% during the 2nd quarter. Pinnacle Associates Ltd. now owns 564,360 shares of the company’s stock worth $2,805,000 after purchasing an additional 33,905 shares during the period. Villere ST Denis J & Co. LLC lifted its holdings in shares of CollPlant Biotechnologies by 1.6% in the 1st quarter. Villere ST Denis J & Co. LLC now owns 366,967 shares of the company’s stock valued at $1,963,000 after buying an additional 5,674 shares during the period. Finally, Benjamin F. Edwards & Company Inc. boosted its stake in shares of CollPlant Biotechnologies by 11.3% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 50,150 shares of the company’s stock valued at $320,000 after buying an additional 5,100 shares in the last quarter. 21.69% of the stock is owned by hedge funds and other institutional investors.

CollPlant Biotechnologies Stock Up 2.4 %

Shares of NASDAQ CLGN traded up $0.11 during mid-day trading on Thursday, hitting $4.60. 1,513 shares of the company were exchanged, compared to its average volume of 9,700. The stock has a 50 day simple moving average of $4.88 and a 200-day simple moving average of $5.30. CollPlant Biotechnologies has a 1-year low of $4.15 and a 1-year high of $7.88. The firm has a market cap of $52.68 million, a price-to-earnings ratio of -6.76 and a beta of 0.24.

CollPlant Biotechnologies (NASDAQ:CLGN) last announced its quarterly earnings data on Wednesday, May 29th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). CollPlant Biotechnologies had a negative return on equity of 24.74% and a negative net margin of 70.58%. The firm had revenue of $0.10 million for the quarter, compared to analysts’ expectations of $0.60 million. Analysts anticipate that CollPlant Biotechnologies will post -1.46 earnings per share for the current fiscal year.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.